Roche drug advances KRAS-driven lung cancer treatment

Roche's experimental drug, divarasib, showed a 50% response rate in patients with KRAS G12C-mutated non-small cell lung cancer, according to new data. This early-stage trial's results suggest a significant improvement over existing treatments like Amgen's Lumakras and Mirati's Krazati, which hover around 30% response rates. It points to a new, more potent option for a form of cancer that's historically been tough to treat.